Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

NGR007: A Phase II Study of NGR-hTNF Administered in Combination With Doxorubicin Every 3 Weeks in Patients Affected by Advanced or Metastatic Small Cell Lung Carcinoma (SCLC) Previously Treated With at Least One Therapeutic Regimen

NCT00483509 is registered in ClinicalTrials.gov with AGC Biologics S.p.A. as lead sponsor.

NCT NCT00483509
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00483509 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
NGR007: A Phase II Study of NGR-hTNF Administered in Combination With Doxorubicin Every 3 Weeks in Patients Affected by Advanced or Metastatic Small Cell Lung Carcinoma (SCLC) Previously Treated With at Least One Therapeutic Regimen
Lead sponsor
AGC Biologics S.p.A.
Phase
Phase 2
Overall status
Completed
Start date
February 14, 2007
Completion date
May 17, 2011
Enrollment
28 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung cancer